Readystate Asset Management LP Sells 288,480 Shares of Celldex Therapeutics, Inc. $CLDX

Readystate Asset Management LP trimmed its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 86.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,520 shares of the biopharmaceutical company’s stock after selling 288,480 shares during the quarter. Readystate Asset Management LP owned approximately 0.07% of Celldex Therapeutics worth $1,203,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in shares of Celldex Therapeutics by 171.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 881 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Celldex Therapeutics in the third quarter valued at approximately $42,000. Russell Investments Group Ltd. boosted its stake in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the last quarter. Strs Ohio bought a new position in Celldex Therapeutics in the third quarter valued at approximately $75,000. Finally, Headlands Technologies LLC acquired a new stake in Celldex Therapeutics during the 2nd quarter worth $125,000.

Celldex Therapeutics Stock Performance

CLDX opened at $23.00 on Thursday. The firm’s fifty day moving average is $25.68 and its two-hundred day moving average is $25.26. The firm has a market cap of $1.53 billion, a PE ratio of -6.80 and a beta of 1.24. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $30.50.

Analysts Set New Price Targets

CLDX has been the topic of a number of analyst reports. Barclays increased their price target on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and an average price target of $41.56.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.